Concepedia

Marita Prohn

MP

Statistics

Publications

10

Citations

375

H-Index

10

Active since

2008

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD (Netherlands)

Marita Prohn is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, pharmacokinetics, and pharmacy.

ORCID

Publications per year

2008–2021

10

Publications

10

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors

Malidi Ahamadi, Tomoko Freshwater, Marita Prohn et al. · CPT Pharmacometrics & Systems Pharmacology · 2016 · 150 citations · Full text

, , +15

Effects of Sugammadex Doses up to 32 mg/kg Alone or in Combination with Rocuronium or Vecuronium on QTc Prolongation

Pieter‐Jan de Kam, Jacqueline van Kuijk, Marita Prohn et al. · Clinical Drug Investigation · 2010 · 54 citations

, , +4

Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects

Pieter‐Jan de Kam, Peter Grobara, Marita Prohn et al. · International Journal of Clinical Pharmacology and Therapeutics · 2014 · 48 citations

, , +17

Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients

Marita Prohn, Anders Viberg, Da‐Lin Zhang et al. · CPT Pharmacometrics & Systems Pharmacology · 2021 · 25 citations · Full text

, , +8

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer

Neeraj Gupta, Xiaohui Wang, Elliot Offman et al. · Clinical Pharmacokinetics · 2020 · 23 citations · Full text

, , +16

1–5 of 10